Skip to main content
BioCentury Conference Center

Bio€quity Europe 2013 Conference Agenda

Tuesday, May 21
20:00 - 22:30

Welcome Networking Reception at Sheraton Hotel
You may pick-up your name badge at the welcome reception. Registration will be open from 20:00 to 21:30
Sponsored by
ABG Sundal Collier

Wednesday, May 22
07:30 - 09:30 Registration opens and Breakfast (Level 1)
08:45 - 09:00 Welcome and Official Greeting from the Organizers (Drottningholmsalen A+B)
09:00 - 09:15 Welcome remarks from Ms Chris Heister, County Governor of Stockholm County
09:15 - 10:15

Plenary 1 (Drottningholmsalen A+B)

The 6th Annual BioCentury - Ernst & Young's Face-Off

BioCentury unveils its 11th annual survey of European biotech's financings needs and Ernst & Young provides analysis of its 27th Annual Beyond Borders Global Biotechnology Report. Included: Commentary from leading decision makers from the strategic and venture capital investment community and the European Commission on what this could mean for life science investment going forward. Panelists include:

Susan Schaeffer, Editor, BioCentury, the Bernstein Report on BioBusiness, BioCentury
Glen Giovannetti, Global Life Sciences Sector Leader, Ernst & Young
Dr. Didier Gambier, Head of Unit Horizontal Aspects of Health, European Commission
Dr. Björn Odlander, Founding Partner, HealthCap
Dr. Michael Shalmi, Senior Partner, Novo Growth Equity
10:15 - 10:45 Break
10:45 - 11:45

Plenary 2 (Drottningholmsalen A)

How should Europe compete in early innovation?

European academics, science-driven biotechs, VCs and pharmas debate what needs to be done to create global value with European science. Panelists include:

Dr. Torbjörn Bjerke, CEO, Karolinska Development AB
Dr. Anders Ekblom, CEO, AstraZeneca Sweden AB
Eric Halioua, CEO, Promethera Biosciences S.A.
Dr. Werner Lanthaler, CEO, Evotec AG
Dr. Tomas Lundquist, Partner, AWA Patent
Dr. Rafaèle Tordjman, Managing Partner, Sofinnova

Plenary 3 (Drottningholmsalen B)

How must European biotech adapt
to the healthcare ecosystem?

Commercial stage biotechs and pharmas dissect the requirements for creating value for payers in Europe and beyond. Panelists include:

Sebastian Alexanderson, Head of Healthcare, ABG Sundal Collier
David Butts, Partner and Head of Lifesciences, CMS
Birgitta Wikman Erlandsson, Head of Nordic Simeprevir, Medivir AB
Dr. Stefan Larsson, Senior Partner and Managing Director, The Boston Consulting Group
Dr. Thomas Lönngren, Strategic Advisor, NDA UK
Dr. Geoffrey McDonough, CEO, Swedish Orphan Biovitrum AB


Stockholm Business Region Showcase (Haga 3)

Stockholm Business Region Elevator Pitches from young Swedish companies

Abera Bioscience AB
BinaryBio AB
BioLamina AB
Biovica International AB
Corline Systems AB
Diamyd Medical AB
Inerventions AB
KeytoLead AB
ModPro AB
Premune AB
Senzime AB
Spiber AB
Xbrane Bioscience AB
XSpray Microparticles AB


11:45 - 12:00 Break

Presentation Rooms

Drottningholmsalen A Drottningholmsalen B St Eriksalen Haga 3
12:00 - 12:25 Anergis S.A. BioAlliance Pharma S.A. (Euronext:BIO) Zealand Pharma A/S (CSE:ZEAL)

Q&A Session
12:00 - 13:00

CEO Bootcamp #4: Stories from the Tranches

For a 4th year, Bio€quity Europe provides core lessons for biotech CEOs, this year focusing on tranching and managing venture rounds. Panelists include:

Dr. Allan Marchington, Partner, Apposite Capital
Dr. Carole Nuechterlein, Head of Roche Venture Fund

Oliver Schacht, CEO, Curetis AG

Sten Verland, Partner, Sunstone Capital
Dr. Christian Zahnd, CEO, Molecular Partners AG

12:30 - 12:55

Genmab A/S (CSE:GEN) Newron Pharmaceuticals S.p.A. (SIX:NWRN) Prosonix Ltd.
13:00 - 14:00 Networking Luncheon (Restaurant, Level 0 & Haga 2, Level 1)
14:00 - 14:25 4SC AG (Xetra:VSC) BoneSupport AB Apogenix GmbH

Q&A Session
14:15 - 15:15

Fireside Chats: War Stories from Those Who Adapted
(Session 1)

Bio€quity Europe continues its tradition of intimate Q&A sessions, this year offering lessons from CEOs who have managed their way through challenging times. Panelists include:

Tim Haines, Partner, Abingworth
Dr. Christian Itin, Chairman & CEO, Cytos Biotechnology AG
Antoine Papiernik, Managing Partner, Sofinnova
Dr. Jan van de Winkel, President & CEO, Genmab A/S
14:30 - 14:55 GlycoVaxyn AG Biotie Therapies Corp. (HSE:BTH1V) Nanobiotix S.A. (Euronext:NANO)
15:00 - 15:25 Wilex AG (Xetra:WL6) Molecular Partners AG Algeta ASA (OSE:ALGETA)
15:30 - 15:55 Complix N.V. NuCana BioMed Ltd. Polyphor Ltd.

Regional & Next Wave Company Presentations

Acesion Pharma ApS
Adenium Biotech ApS
Aniona ApS
Axcentua Pharmaceuticals AB
Cormorant Pharmaceuticals AB
Wilson Therapeutics AB
Oncology Venture ApS
Oncorena AB
Oncos Therapeutics Ltd.
OxThera AB
Galecto Biotech AB
Peptonic Medical AB
KalVista Pharmaceuticals Ltd.
Lead Pharma Holding B.V.
Mission Therapeutics Ltd.
re:Viral Ltd.
Sensorion S.A.S.
Signature Diagnostics AG

16:00 - 16:25 Oryzon Genomics S.A. Nuevolution A/S Promethera Biosciences S.A.
16:30 - 16:55 Lanthio Pharma B.V. Evotec AG (Xetra:EVT) Vaximm AG
17:00 - 17:25 Avelas Biosciences Inc. MorphoSys AG (Xetra:MOR; Pink:MPSYF) Creabilis S.A.
17:30 - 17:55 Auxogyn Inc. Protagen AG Genkyotex S.A.
18:00 - 18:25 Virobay Inc. Trophos S.A. Orexo AB (SSE:ORX)
18:30 - 19:00 Transition to Networking Reception
19:00 Networking Reception and Dinner at 'Berns' in the Stora Salongen
Sponsored by The Regional Host Committee
Thursday, May 23
07:45 - 09:00 Registration opens and Breakfast (Level 1)

Presentation Rooms

Drottningholmsalen A Drottningholmsalen B St Eriksalen Haga 3
09:00 - 09:25 Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Cytos Biotechnology AG (SIX:CYTN)

Next Wave Company Presentations

Asceneuron S.A.
BioVersys AG
Ability Pharmaceuticals S.L.
BioXpress Therapeutics S.A.
Canbex Therapeutics Ltd.
Enterome Bioscience
Hookipa Biotech AG
Immune Targeting Systems Ltd.
Oxford Cancer Biomarkers Ltd
Prexton Therapeutics S.A.
FIT Biotech Oyj Plc
ProteoMediX AG
Targovax A/S
to-BBB technologies B.V.

Q&A Session
09:00 - 10:00

Fireside Chats: War Stories from Those Who Adapted
(Session 2)

Bio€quity Europe continues its tradition of intimate Q&A sessions, this year offering lessons from CEOs who have managed their way through challenging times. Panelists include:

David Bejker, CEO, Affibody AB
Mattias Häggblom, Senior Analyst, Danske Bank
Ken Moch, President & CEO, Chimerix Inc.
Dr. Mårten Steen, Partner, HealthCap
Nikolaj Sorensen, CEO, Orexo AB
09:30 - 09:55 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Transgene S.A. (Euronext:TNG)
10:00 - 10:25 Sygnis Pharma AG (Xetra:LIO1) EpiTherapeutics ApS

Ernst & Young - Breakout Session
10:15 - 11:15

The E&Y Breakout

Ernst & Young's team digs into the data and provides further analysis of their findings from their 27th Annual Beyond Borders Global Biotechnology Report

Dr. Siegfried Bialojan, Executive Director, Head, European Life Science Center, Ernst & Young
Dr. Jörg Zürcher, Partner, Biotechnology Leader EMEIA, Ernst & Young
10:30 - 10:55 Vivus Inc. (NASDAQ:VVUS) Amakem N.V.
11:00 - 11:25 AM-Pharma B.V. Verona Pharma plc (LSE:VRP)
11:30 - 11:55 TiGenix N.V. (Euronext:TIG)   Poxel S.A.

Q&A Session
11:30 - 12:30

Exit Strategies

Do exit expectations need to be recalibrated again? Strategic and financial investors debate the future of asset development models. Panelists include:

Roel Bulthuis, Head of Merck Serono Ventures
Dr. John Haurum, CEO, F-star GmbH
Dr. Kevin Johnson, Partner, Index Ventures
Niall McAlister, Partner, Edwards Wildman
Graziano Seghezzi, Partner, Sofinnova Partners
Al Sokol, Partner, Edwards Wildman
12:00 - 12:25 Covagen AG Piqur Therapeutics AG Diaxonhit (Euronext:ALEHT)
12:30 - 13:30 Networking Luncheon (Restaurant, Level 0 & Haga 2, Level 1)
13:30 - 13:55 Nano Bridging Molecules S.A. Curetis AG Immune Pharmaceuticals Ltd.  
14:00 - 14:25 Gene Signal International S.A. Noxxon Pharma AG Prosensa B.V.
14:30 - 14:55 OctreoPharm Sciences GmbH Forward Pharma A/S Shield Therapeutics AG
15:00 - 15:25 PledPharma AB (SSE:PLED) Sequana Medical AG CureVac GmbH
15:30 - 15:55 Epigenomics AG (Xetra:ECX) vasopharm GmbH InDex Pharmaceuticals AB
16:00 - 16:45

Closing Plenary with Champagne (Drottningholmsalen C)

Recipes For Success

Seasoned corporate and institutional VCs share their lessons for succeeding and debate the current European and global investment ecosystem. Also on tap: What 'ingredients' are required to nuture innovators in Europe and elsewhere? Panelists include:

Dr. Francesco de Rubertis, Partner, Index Ventures
Dr. David Donabedian, Managing Director, AbbVie Biotech Ventures
Dr. Maciek Drozdz, Investment Manager, Entrepreneurs Fund
Simon Meier, Investment Director, Roche Venture Fund
Isai Peimer, Principal, MedImmune Ventures